Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing’s Sarcoma Family of Tumours
Aug 30, 2018The objective of the induction/consolidation chemotherapy randomisation (R1) is to compare the VIDE strategy (VIDE induction and VAI/VAC/BuMel consolidation) with the VDC/IE strategy (compressed VDC/IE induction and IE/VC/Bu-Mel consolidation). The e...
Clinical Studies - Aug 30, 2018 - Aug 14, 2014
Automatically Closed
Project leader: Appenzeller Christina
Alternate day dosing of Pomalidomide in patients with re-fractory Multiple
Aug 17, 2018Multiple myeloma (MM) accounts for 1% of all cancers and ∼10% of all hematological malignancies. Despite recent advances in myeloma treatment, including the introduction of proteasome inhibitors, immunomodulatory drugs (IMiDs) and stem cell transplan...
Clinical Studies - Aug 17, 2018 - Apr 23, 2023
Automatically Closed
Project leader: Silzle Tobias
Tailored AXILLary Surgery with or without axillary lymph node dissection followed by radotherapy in patients with clinically node-positive breast cancer (TAXIS)
Jul 30, 2018The removal of all lymph nodes in the armpit through con-ventional axillary dissection has been standard care for all patients with breast cancer for almost a century. In the nineties, the sentinel lymph node (SLN) procedure, which involves the selec...
Clinical Studies - Jul 30, 2018 - Dec 12, 2030
Ongoing
Project leader: Bekes Inga
Members: Sennhauser Andrina, Müller Fiona
An Observatinal Study of Blinatumomab Safety and Effec-tiveness, Utillisation, and Treatment Practice
Jul 11, 2018Study Background and Rationale As a new treatment for acute lymphoblastic leukaemia (ALL), it is important tounderstand the safety and effective-ness of Blincyto (blinatumomab) as it isadministered in routine clinical practice. This study, developed...
Clinical Studies - Jul 11, 2018 - Feb 22, 2022
Automatically Closed
Project leader: Silzle Tobias
Randomisierte, offene, multizentrische Phase-2/3-Studie zur Beurteilung der Wirksamkeit und Sicherheit von Ro-garatinib (BAY 1163877) im Vergleich zu Chemotherapie bei Patienten mit FGFR-positivem, lokal fortgeschritte-nem oder metastatischem Urothelkarzinom, die vorher eine platinhaltige Chemotherapie erhalten haben
May 30, 2018Rogaratinib ist ein oraler pan-FGFR inhibitor. Eine FGFR-Überexpression (vorallem FGFR3 isoform) kann in bis zu 40% aller Patienten mit metastasiertem Urothelkarzinom nachgewiesen werden und stellt einen oncogenic driver da. Die Studie untersucht Rog...
Clinical Studies - May 30, 2018 - Dec 31, 2030
Ongoing
Project leader: Schmid Sabine
Patient-needs-based multi-professional delivery of Palliative Interventions by oncologists’ and oncology nurses: a randomized Phase II trial
May 22, 2018Background: Evidence is emerging that early specialist palliative care (SPC) is effective in several defined clinical settings and that it consists of a variety of definable palliative interventions (PCI). PCI encompass pharmacological, procedural, e...
Clinical Studies - May 22, 2018 - May 22, 2018
Automatically Closed
Members: Schmidt Mary Helen, Domeisen Benedetti Franzisca, Attoun-Knobel Suzanne, Behnke Nadine
Multicentre Oberservational Study of MDS Patients in Switzerland- Swiss MDS Registry
May 17, 2018Die Myelodysplastischen Syndrome (MDS) umfassen eine heterogene Gruppe hämatologischer Stammzellerkran-kungen, welche durch Reifungsstörungen des Knochen-markes (Dysplasien) mit Verminderung der Blutzellen (Zy-topenien) charakterisiert sind. Das Spek...
Clinical Studies - May 17, 2018 - Aug 14, 2030
Ongoing
Project leader: Silzle Tobias
Members: Steiner Marianne
TRIANGLE: autologous Transplantation after a Rituxi-mab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European mcl net-work trial
Feb 20, 2018According to current European guidelines (Dreyling, Ann Oncol 2014), the standard of care in younger patients with mantle cell lymphoma (MCL) is a dose-intensified approach with a cytarabine containing immunochemotherapy induction followed by autolog...
Clinical Studies - Feb 20, 2018 - Jan 31, 2028
Ongoing
Project leader: Hitz Felicitas
Protocol SAKK 07/17: Nivolumab in combination with I-pilimumab in patients with metastatic renal cell carcinoma: A multicentre single-arm phase lI trial
Jan 4, 2018Superior overall survival of PD-1 blockade with nivolumab compared to everolimus has been shown in the phase III Checkmate-025 trial in metastatic clear cell carcinoma of the kidney in second line after progression under first line therapy with a tyr...
Clinical Studies - Jan 4, 2018 - Oct 31, 2021
Automatically Closed
Project leader: Rothermundt Christian
Effect of induction chemotherapy on lung function measured by spiroergometry and 6-Minute walking test in patients affected by non-small cell lung cancer (NSCLC)
Jan 1, 2018Lung cancer is one of the most common cancers in the world and the leading cause of cancer-related mortality. At diagnosis, approximately 40% of patients are already at an advanced stage, and a third have locally advanced disease (stage III). Stage I...
Fundamental Research - Jan 1, 2018 - Dec 31, 2020
Automatically Closed
Members: Baty Florent, Brutsche Martin, Kern Lukas, Maeder Micha, Früh Martin
A Phase 2, multi-center, open label study of NIR178 in combination with PDR001 in patients with selected ad-vanced solid tumors and non-Hodgkin lymphoma
Oct 5, 2017This is a multi-center, open label, phase 2 study to evaluate efficacy of the NIR178 and PDR001 combination in NSCLC, other solid tumors, and diffuse large B-cell lymphoma (DLBCL). The study has three parts: part 1: Multi-arm Bayesian adaptive signal...
Clinical Studies - Oct 5, 2017 - Feb 20, 2024
Automatically Closed
Project leader: Jörger Markus
SAKK 17/16: Lurbinectedin Monotherapy in Pa-tients with Progressive Malignant Pleural Mesothelioma. A Multicenter, Single-arm Phase II Trial
Sep 29, 2017Malignant mesothelioma arises from the mesothelial cells of the pleural, peritoneal or pericardial lining and is often associated with asbestos exposition (Robinson, 2005). There is no cure for most malignant mesotheliomas and the scope of all three...
Clinical Studies - Sep 29, 2017 - Sep 29, 2021
Automatically Closed
Project leader: Früh Martin
Randomisierte, doppelblinde, placebokontrollierte Pha-se III-Studie zu Rovalpituzumab Tesirin als Erhaltungs-therapie nach einer Erstlinienchemotherapie auf Platin-basis bei Studienteilnehmern mit ausgebreitetem (exten-sive-stage) kleinzelligem Bronchialkarzinom (MERU)
Sep 22, 2017Industrie gesponserte Studie zur Evaluation der Wirksamkeit (hinsichtlich OS und PFS) von Rovalpituzumab Tesirin beim SCLC, eingesetzt als Erhaltungstherapie nach Erstli-nientherapie. Rovalpituzumab Tesirin ist ein Antikörper-Wirkstoff Konju-gat, wob...
Clinical Studies - Sep 22, 2017 - Mar 31, 2019
Automatically Closed
Project leader: Früh Martin
The MENAC Trial - A randomised, open-label trial of a multimodal intervention (multimodal = exercise, nutrition and anti-inflammatory medication) versus standard care in cancer patients with cachexia
Aug 24, 2017Cachexia is a common detrimental consequence of cancer limiting therapy, quality of life and survival. There is no standard treatment available and its complex multifactorial pathophysiology requires multimodal treatment. Based on promising phase II...
Clinical Studies - Aug 24, 2017 - May 31, 2020
Automatically Closed
Project leader: Strasser Florian, Domeisen Benedetti Franzisca
Members: Attoun-Knobel Suzanne, Behnke Nadine
CLL13-TRIAL OF THE GCLLSG IN COOPERATION WITH HOVON, NORDIC CLL STUDY GROUP AND SAKK (THE GA101 IBRUTINIB ABT101 (GAIA) TRIAL): A PHASE 3 MULTICENTER, RANDOMIZED, PROSPECTIVE, OPEN-LABEL TRIAL OF STANDARD CHEMOIMMUNOTHERAPY (FCR/BR) VERSUS RITUXIMAB PLUS VENETOCLAX (RVE) VERSUS OBINUTUZUMAB (GA101) PLUS VENETOCLAX (GVE) VERSUS OBINUTUZUMAB PLUS IBRUTINIB PLUS VENETOCLAX (GIVE) IN FIT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITHOUT DEL(17P) OR TP53 MUTATION
Jul 17, 2017Chemoimmunotherapy is the standard of care in first-line treatment of CLL patients without del17p or TP 53 mutation; physically fit patients are treated with fludarabine, cyclophosphamide and rituximab (FCR)1. Due to the high risk of severe neutropen...
Clinical Studies - Jul 17, 2017 - Feb 29, 2024
Automatically Closed
Project leader: Baumann Michael
QLQ-CAX24 Phase4
Jul 17, 2017The aim of the present study is to test the scale structure, reliability, responsiveness to change and validity of the EORTC QLQ-CAX24 in conjunction with the EORTC QLQ-C30 in people diagnosed with cancer cachexia with different primary cancer diagno...
Clinical Studies - Jul 17, 2017 - Oct 1, 2017
Automatically Closed
Project leader: Strasser Florian
Members: Domeisen Benedetti Franzisca, Attoun-Knobel Suzanne
Preclinical investigation of cardiotoxicity as a clinically important side effect of proteasome inhibitor-based therapy
Jul 1, 2017Carfilzomib is the recently approved second generation proteasome inhibitor for multiple myeloma therapy. Carfilzomib has superior clinical activity than the first generation drug, bortezomib, putatively due to less off-target activity and an altered...
Fundamental Research - Jul 1, 2017 - Jun 30, 2018
Automatically Closed
Project leader: Besse Lenka
Members: Mendez Lopez Max
ETOP 10-16 BOOSTER: A randomised phase II trial of osimertinib and bevacizumab versus osimertinib alone as second-line treatment in stage IIIb-IVb NSCLC with con-firmed EGFRm and T790M
Jun 15, 2017First-generation EGFR tyrosine kinase inhibitors provide significant clinical benefit in patients with advanced EGFR-mutant (EGFRm) non–small cell lung carcinoma (NSCLC). However, all patients ultimately develop disease progres-sion, driven – as the...
Clinical Studies - Jun 15, 2017 - Oct 26, 2023
Automatically Closed
Project leader: Früh Martin
HD21 for advanced stages: Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 6 cy-cles of escalated BEACOPP with 6 cycles of BrECADD
Jun 9, 2017With the establishment of polychemotherapy and the con-tinuous advancements in radiotherapy, Hodgkin lymphoma has meanwhile become a malignant oncological disease in adults with one of the best prognoses of all. The outcome improvements in Hodgkin ly...
Clinical Studies - Jun 9, 2017 - Sep 30, 2021
Automatically Closed
Project leader: Hitz Felicitas
SAKK 19/16:Binimetinib, pemetrexed and cisplatin, followed by maintenance with binimetinib and pemetrexed, in patients with advanced non-small cell lung cancer with KRAS mutationsA multicenter phase IB trial
Apr 25, 2017There is a need for more effective therapies for patients with advanced NSCLC driven by the RAS/MEK/ERK pathway. These tumors are generally aggressive, are almost exclusively of non-squamous histology, and represent the largest group of patients with...
Clinical Studies - Apr 25, 2017 - Nov 30, 2019
Automatically Closed
Project leader: Früh Martin